biotech / news / / The Manila Times
Led by OrbiMed, with participation from RA Capital Management, Janus Henderson Investors, Sanofi Ventures, Harbour BioMed, and existing investors.Proceeds will advance lead candidate WIN378 into Phase 3 and WIN027 into respiratory and dermatology studies by Q4 2026.
Windward Bio raised $165M in crossover financing, including new investors RA Capital and Sanofi Ventures.
KEY POINTS
- WIN378's Phase 2/3 asthma study POLARIS is fully recruited, with initial data expected in late 2026.
- WIN378 enables twice-yearly dosing and could become the first ultra long-acting anti-TSLP for asthma and COPD.
- WIN027 is a bispecific antibody targeting TSLP and IL-13; proof-of-concept studies begin in Q4 2026.
COMPANIES
Summarized by Newsio from The Manila Times. How we summarize →